NFE2L2 and cancer: Despite this fact, targeting NRF2 and its downstream targets remains a viable approach for utilizing ferroptosis to kill resistant cancer cells until a more specific inhibitor of NRF2 or other druggable downstream ferroptotic pathway targets are identified.